Mga Batayang Estadistika
| LEI | 54930027ZPNA80B8O763 |
| CIK | 1469443 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Arcadia Biosciences, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2025 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 14, 2025 |
Arcadia Biosciences, Inc. Consolidated Balance Sheets (In thousands, except share data) Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 1,376 $ 4,242 Short-term investments 3,067 — Accounts receivable and other receivables, net of allowance for credit losses of $559 and $0 as of June 30, 2025 and December 31, 2024, respectively 1,264 1,17 |
|
| August 14, 2025 |
Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2025 Financial Results and Business Highlights - Arcadia revenues increase 11% year over year driven by 24% growth in Zola® - - Arcadia receives 2.7 million shares of stock in ABVE - - Arcadia eliminates $1M in liabilities - DALLAS, Texas (August 14, 2025) – Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and mar |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 14, 2025 |
Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2025 Financial Results and Business Highlights - Arcadia revenues increase 11% year over year driven by 24% growth in Zola®- - Arcadia receives 2.7 million shares of stock in ABVE - - Arcadia eliminates $1M in liabilities - DALLAS, Texas (August 14, 2025) – Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and mark |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 14, 2025 |
Arcadia Biosciences, Inc. Consolidated Balance Sheets (In thousands, except share data) Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 1,376 $ 4,242 Short-term investments 3,067 — Accounts receivable and other receivables, net of allowance for credit losses of $559 and $0 as of June 30, 2025 and December 31, 2024, respectively 1,264 1,17 |
|
| July 31, 2025 |
Consent of Advance Resources International, Inc. Exhibit 99.8 ADVANCED RESOURCES INTERNATIONAL, INC. RESEARCH AND DEVELOPMENT CONSULTANTS CONSENT OF CONSULTANTS As an independent consulting, research and development firm providing services related to unconventional gas, enhanced oil recovery and carbon capture, utilization and storage (the “Services”), we hereby consent to the inclusion of information included or incorporated by reference in thi |
|
| July 31, 2025 |
Exhibit 10.42 OVERHEAD SHARING AGREEMENT This Overhead Sharing Agreement (the “Agreement”), dated effective as of January 1, 2025 (the “Effective Date”), is by and between Roosevelt Investments, LP, a Texas limited partnership (“RILP”) and Roosevelt Resources, LP, a Texas limited partnership (“RRLP”) (collectively, the “Parties”). RECITALS The Parties share office space located at 5956 Sherry Lane |
|
| July 31, 2025 |
Consent of Northland Securities, Inc. Exhibit 99.1 CONSENT OF NORTHLAND SECURITIES, INC. We hereby consent to the use of our opinion letter dated December 3, 2024, to the Board of Directors of Arcadia Biosciences, Inc., included as Annex B to the proxy statement/prospectus which forms a part of Amendment No. 1 to the Registration Statement on Form S-4 of Arcadia Biosciences, Inc., to be filed on or about the date hereof, and to the re |
|
| July 31, 2025 |
Article V-A REPRESENTATIONS AND WARRANTIES OF THE LIMITED PARTNERS As filed with the Securities and Exchange Commission on July 30, 2025 Registration No. |
|
| July 31, 2025 |
Amended and Restated Loan Agreement dated as of March 29, 2024, by and among Roosevelt Resources Exhibit 10.39 AMENDED AND RESTATED LOAN AGREEMENT DATED AS OF MARCH 29, 2024 among ROOSEVELT RESOURCES LP, YOAKUM COUNTY MINERALS, L.P., and ER ROLLING R RANCH PARTNERS, LP, as Borrower and PROSPERITY BANK, successor by merger to FirstCapital Bank of Texas, N.A., as Lender AMENDED AND RESTATED LOAN AGREEMENT THIS AMENDED AND RESTATED LOAN AGREEMENT (as the same has been or may be amended, restated |
|
| July 31, 2025 |
Exhibit 10.40 FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AGREEMENT This FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AGREEMENT (this “Amendment”) is entered into effective as of December 9, 2024 (the “First Amendment Effective Date”) among ROOSEVELT RESOURCES LP, a Texas limited partnership (“Resources”), YOAKUM COUNTY MINERALS, L.P., a Texas limited partnership (“YCM”), E R ROLLING R RANCH PART |
|
| July 31, 2025 |
Exhibit 10.41 SECOND AMENDMENT TO AMENDED AND RESTATED LOAN AGREEMENT This SECOND AMENDMENT TO AMENDED AND RESTATED LOAN AGREEMENT (this “Amendment”) is entered into effective as of June 17, 2025 (the “Second Amendment Effective Date”) among ROOSEVELT RESOURCES LP, a Texas limited partnership (“Resources”), YOAKUM COUNTY MINERALS, L.P., a Texas limited partnership (“YCM”), E R ROLLING R RANCH PART |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2025 |
Arcadia Biosciences, Inc. Consolidated Balance Sheets (In thousands, except share data) Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) March 31, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 3,159 $ 4,242 Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 as of March 31, 2025 and December 31, 2024 1,615 1,175 Inventories — current 1,285 904 Note receivabl |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2025 |
Arcadia Biosciences, Inc. Consolidated Balance Sheets (In thousands, except share data) Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) March 31, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 3,159 $ 4,242 Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 as of March 31, 2025 and December 31, 2024 1,615 1,175 Inventories — current 1,285 904 Note receivabl |
|
| May 8, 2025 |
Agreement between Bioceres and Arcadia dated as of March 28, 2025 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO ARCADIA BIOSCIENCES, INC. IF PUBLICLY DISCLOSED AGREEMENT BETWEEN BIOCERES AND ARCADIA This Agreement (the “Agreement”) is entered into as of March 28, 2025, by and between: BIOCERES CROP SOLUTIONS, CORP., with its princip |
|
| May 8, 2025 |
Exhibit 99.1 Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business Highlights - Revenues increase 22% year over year driven by 90% growth in Zola® - - Arcadia sells patents for $750K and eliminates $1M in liabilities - - Roosevelt agreement amended to provide greater certainty regarding exchange ratio - DALLAS, Texas (May 8, 2025) – Arcadia Biosciences, Inc.® (Nasd |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2025 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2025 |
Exhibit 99.1 Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business Highlights - Revenues increase 22% year over year driven by 90% growth in Zola® - - Arcadia sells patents for $750K and eliminates $1M in liabilities - - Roosevelt agreement amended to provide greater certainty regarding exchange ratio - DALLAS, Texas (May 8, 2025) – Arcadia Biosciences, Inc.® (Nasd |
|
| May 2, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 2, 2025 |
First Amendment to Securities Exchange Agreement. Exhibit 2.1 FIRST AMENDMENT TO SECURITIES EXCHANGE AGREEMENT This First Amendment to Securities Exchange Agreement (the "Amendment") is dated as of April 25, 2025 (the "Effective Date") and is entered into by and among (i) Arcadia Biosciences, Inc., a Delaware corporation (the “Company”), (ii) Roosevelt Resources, LP, a Texas limited partnership ("Roosevelt" or the “Partnership”), and (iii) Elliot |
|
| May 2, 2025 |
First Amendment to Securities Exchange Agreement. Exhibit 2.1 FIRST AMENDMENT TO SECURITIES EXCHANGE AGREEMENT This First Amendment to Securities Exchange Agreement (the "Amendment") is dated as of April 25, 2025 (the "Effective Date") and is entered into by and among (i) Arcadia Biosciences, Inc., a Delaware corporation (the “Company”), (ii) Roosevelt Resources, LP, a Texas limited partnership ("Roosevelt" or the “Partnership”), and (iii) Elliot |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission F |
|
| April 30, 2025 |
Insider Trading Disclosure Policy Exhibit 19.1 Insider Trading and Disclosure Policy This document sets forth the policy (the “Policy”) regarding trading in the stock and other securities of Arcadia Biosciences, Inc., a Delaware corporation (the “Company”), and, where applicable, the disclosure of such transactions. All references to the “Company” in the document include any subsidiaries of Arcadia Biosciences, Inc. The Policy is |
|
| April 3, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 25, 2025 |
EXHIBIT 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of each class of securities of Arcadia Biosciences, Inc. (“Arcadia,” "the company," “we,” “us,” “our”) that is registered under Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is based upon our certificate of i |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-373 |
|
| March 20, 2025 |
Arcadia Biosciences, Inc. Consolidated Balance Sheets (In thousands, except share data) Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) As of December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 4,242 $ 6,518 Short-term investments — 5,124 Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 as of December 31, 2024 and 2023 1,175 506 Inventories, net — current 904 |
|
| March 20, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 20, 2025 |
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2024 Financial Results and Business Highlights - Year-over-year revenues grew 56% in Q4 and 13% for full year - - Zola® year-over-year revenues increased 124% in Q4 and 46% for full year - - Company plans business combination with Roosevelt Resources, Inc. |
|
| February 14, 2025 |
As filed with the Securities and Exchange Commission on February 14, 2025 As filed with the Securities and Exchange Commission on February 14, 2025 Registration No. |
|
| February 14, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) ARCADIA BIOSCIENCES, INC. |
|
| February 14, 2025 |
Consent of Director Nominee (Elliott Roosevelt, Jr.). Exhibit 99.3 Elliott Roosevelt, Jr. c/o Roosevelt Resources, LP 5956 Sherry Lane, Suite 215 Dallas, TX 75225 Consent to Reference in Proxy Statement/Prospectus Arcadia Biosciences, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith |
|
| February 14, 2025 |
Consent of Northland Securities, Inc. Exhibit 99.1 CONSENT OF NORTHLAND SECURITIES, INC. We hereby consent to the use of our opinion letter dated December 3, 2024, to the Board of Directors of Arcadia Biosciences, Inc., included as Annex B to the proxy statement/prospectus which forms a part of the Registration Statement on Form S-4 of Arcadia Biosciences, Inc., to be filed on or about the date hereof, and to the references to us and |
|
| February 14, 2025 |
Consent of Director Nominee (G. Larry Lawrence). Exhibit 99.6 G. Larry Lawrence c/o Roosevelt Resources, LP 5956 Sherry Lane, Suite 215 Dallas, TX 75225 Consent to Reference in Proxy Statement/Prospectus Arcadia Biosciences, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I h |
|
| February 14, 2025 |
Consent of Director Nominee (Jimmy C. Hawkins). Exhibit 99.4 Jimmy C. Hawkins c/o Roosevelt Resources, LP 5956 Sherry Lane, Suite 215 Dallas, TX 75225 Consent to Reference in Proxy Statement/Prospectus Arcadia Biosciences, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I he |
|
| February 14, 2025 |
Consent of Director Nominee (L. Stephen Melzer). Exhibit 99.5 L. Stephen Melzer c/o Roosevelt Resources, LP 5956 Sherry Lane, Suite 215 Dallas, TX 75225 Consent to Reference in Proxy Statement/Prospectus Arcadia Biosciences, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I h |
|
| December 11, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 11, 2024 |
Arcadia Biosciences & Roosevelt Resources Business Combination December 2024 Filed by Arcadia Biosciences, Inc. |
|
| December 11, 2024 |
Arcadia Biosciences & Roosevelt Resources Business Combination December 2024 Filed by Arcadia Biosciences, Inc. |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 04, 2024 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 6, 2024 |
Exhibit 99.1 Arcadia Biosciences Contact: Roosevelt Resources Contact: Sue Wandell Jerrel Branson [email protected] [email protected] ARCADIA BIOSCIENCES (RKDA) ENTERS INTO BUSINESS COMBINATION AGREEMENT WITH ROOSEVELT RESOURCES IN ALL-STOCK TRANSACTION - Companies to host a joint investor call on December 11, 2024 at 4:30 p.m. ET - Dallas, Texas (December 5, 2024) – Arcadia Bioscience |
|
| December 6, 2024 |
Execution Copy EXHIBIT 2.1 SECURITIES EXCHANGE AGREEMENT by and among ARCADIA BIOSCIENCES, INC., ROOSEVELT RESOURCES, LP, AND ELLIOTT ROOSEVELT JR. AND DAVID A. ROOSEVELT, in their capacities as Representatives of the Limited Partners dated as of December 4, 2024 TABLE OF CONTENTS Page Article I DEFINITIONS 2 Section 1.1 Definitions 2 Article II EXCHANGE 12 Section 2.1 Agreement to Exchange 12 Sec |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 04, 2024 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 22, 2024 |
Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 ARCADIA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 81-0571538 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 5950 Sherry Lane, Suite 215 Da |
|
| November 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Arcadia Biosciences, Inc. |
|
| November 12, 2024 |
Arcadia Biosciences (RKDA) Announces Strong Third Quarter 2024 Financial Results and Business Highlights - Total revenues increased 18% compared to Q3 2023 – - Zola® coconut water revenues grew 55% year over year - - Zola retail distribution expanded 68% vs. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. |
|
| November 12, 2024 |
Arcadia Biosciences, Inc. Consolidated Balance Sheets (In thousands, except share data) Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) September 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 3,936 $ 6,518 Short-term investments 2,640 5,124 Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 as of September 30, 2024 and December 31, 2023 882 506 Invento |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 02, 2024 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorp |
|
| August 23, 2024 |
Employment Letter and Severance and Change in Control Agreement for Thomas J. Schaefer August 20, 2024 Thomas Schaefer [Address] Dear Thomas: This letter sets forth the terms of your employment as Chief Executive Officer of Arcadia Biosciences, Inc. |
|
| August 23, 2024 |
Employment Letter and Severance and Change in Control Agreement for Mark Kawakami August 20, 2024 Mark Kawakami [Address] Dear Mark: This letter sets forth the terms of your employment as Chief Financial Officer of Arcadia Biosciences, Inc. |
|
| August 13, 2024 |
Arcadia Biosciences (RKDA) Announces Second-Quarter and First-Half 2024 Financial Results and Business Highlights - Company closes $4M transaction with Corteva Agriscience - - Above Food Corp acquires GoodWheatTM brand - - Zola® coconut water sales increase 42% year over year - Dallas, Texas (August 13, 2024) – Arcadia Biosciences, Inc. |
|
| August 13, 2024 |
Exhibit 10.5 ARCADIA BIOSCIENCES, INC. 2015 OMNIBUS EQUITY INCENTIVE PLAN (As Amended ) 1. Purposes of the Plan. The purposes of this Plan are (a) to attract and retain the best available personnel to ensure the Company’s success and accomplish the Company’s goals; (b) to incentivize Employees, Directors and Independent Contractors with long-term equity-based compensation to align their interests |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. |
|
| August 13, 2024 |
Arcadia Biosciences, Inc. Consolidated Balance Sheets (In thousands, except share data) Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) June 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 5,504 $ 6,518 Short-term investments 2,604 5,124 Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 as of June 30, 2024 and December 31, 2023 840 506 Inventories — cur |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2024 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 02, 2024 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 8, 2024 |
Separation Agreement for Stanley Jacot Jr. Exhibit 10.1 SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (“Agreement”) is entered into by and between Stanley Jacot, Jr. (“Jacot” or “Employee”) on the one hand and Arcadia Biosciences, Inc., a Delaware corporation (“Arcadia” or “Company”) on the other hand. The parties may hereinafter be referred to individually as a “Party” or collectively as the “Parties.” BACKGROUND |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 20, 2024 |
ARCADIA BIOSCIENCES, INC. UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.1 ARCADIA BIOSCIENCES, INC. UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION On May 14, 2024 Arcadia Biosciences, Inc. (“Arcadia” or the “Company”) completed the sale of its GoodWheat business (“Disposition”) to Above Food Corp. (“Above Food” or the “Buyer”). Pursuant to the Asset Purchase Agreement (“Agreement”), the Company sold its GoodWheat business to Above Food for considera |
|
| May 20, 2024 |
Exhibit 10.3 SECURITY AGREEMENT This Security Agreement (“Agreement”), is made as of the May 14, 2024, by and among ABOVE FOOD CORP. a corporation formed under the laws of Saskatchewan (“Parent”), ABOVE FOOD INGREDIENTS CORP., a Delaware corporation and wholly-owned subsidiary of Parent (“Subsidiary”, and together with Parent, “Debtor”), and Arcadia Biosciences, Inc., a Delaware corporation (“Secu |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 20, 2024 |
EXHIBIT 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED ASSET PURCHASE AGREEMENT BY AND AMONG ARCADIA BIOSCIENCES, INC., ARCADIA WELLNESS, LLC, ABOVE FOOD CORP. AND ABOVE FOOD INGREDIENTS CORP. DATED AS OF MAY 14, 2024 . CONTENTS Clause Page Article I : PURCH |
|
| May 20, 2024 |
Exhibit 10.2 PROMISSORY NOTE $6,000,000 May 14, 2024 1. Interpretation. This Promissory Note (“Promissory Note”) is made pursuant to and in connection with that certain Asset Purchase Agreement of even date herewith by and among Arcadia Biosciences, Inc., a Delaware corporation (“Arcadia”), Arcadia Wellness, LLC, a Delaware limited liability company and wholly-owned subsidiary of Arcadia, ABOVE FO |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 17, 2024 |
EXHIBIT 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED ASSET PURCHASE AGREEMENT by and BETWEEN ARCADIA BIOSCIENCES, INC. (“Seller”), and pioneer hi-bred international, inc. (“Purchaser”) Dated as of MAY 13, 2024 ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE A |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. |
|
| May 9, 2024 |
Exhibit 99.1 Arcadia Biosciences (RKDA) Announces First Quarter 2024 Financial Results and Business Highlights – Revenues increase sequentially and year-over-year – – Loss from continuing operations is at lowest level in 6 years – DALLAS, Texas (May 9, 2024) – Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released |
|
| May 9, 2024 |
Arcadia Biosciences, Inc. Consolidated Balance Sheets (In thousands, except share data) Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) March 31, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 3,317 $ 6,518 Short-term investments 5,184 5,124 Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 as of March 31, 2024 and December 31, 2023 760 514 Inventories — c |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission F |
|
| March 28, 2024 |
Exhibit 97.1 ARCADIA BIOSCIENCES, INC. EXECUTIVE OFFICER CLAWBACK POLICY Approved by the Board of Directors on November 29, 2023 (the “Adoption Date”) I. Purpose This Executive Officer Clawback Policy describes the circumstances under which Covered Persons of Arcadia Biosciences, Inc. and any of its direct or indirect subsidiaries (the “Company”) will be required to repay or return Erroneously-Awa |
|
| March 28, 2024 |
EXHIBIT 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of registered securities of Arcadia Biosciences, Inc. (“Arcadia,” “we,” “us,” “our”) is based upon our certificate of incorporation, as amended (“Certificate of Incorporation”) and bylaws, as amended (“Bylaws”) and does not purport to be complete |
|
| March 28, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 28, 2024 |
Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2023 Financial Results and Business Highlights - Second continuous year of gross profit growth - - Total SG&A expenses declined to the lowest levels since 2019 - - GoodWheatTM now in more than 3,500 stores with better-for-you pasta, pancake/waffle mixes and mac & cheese - DALLAS, Texas (March 28, 2024) – Arcadia Bioscie |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-373 |
|
| March 28, 2024 |
Arcadia Biosciences, Inc. Consolidated Balance Sheets (In thousands, except share data) Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) As of December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 6,518 $ 20,644 Short-term investments 5,124 — Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 and $3 as of December 31, 2023 and 2022, respectively 514 1,221 Inventori |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 08, 2024 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 14, 2024 |
Separation Agreement for Laura Pitlik Exhibit 10.1 February 9, 2024 Laura Pitlik ####### ####### Dear Laura: As discussed, you notified Arcadia Biosciences, Inc. (the "Company") on February 9, 2024, that you were resigning as an employee of the Company, effective March 1, 2024. This letter of agreement ("Agreement") sets forth the terms and conditions of your separation from employment with the Company. 1. Separation. Your date of vol |
|
| February 14, 2024 |
US0390143032 / ARCADIA BIOSCIEN / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 9, 2023 |
Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Strong Third Quarter 2023 Financial Results and Business Highlights - Increased revenue from continuing operations 20% quarter over quarter - - Lowest SG&A expenses since 2019 - - GoodWheat™ expanding into third category with upcoming launch of Mac & Cheese - Dallas, Texas (November 9, 2023) – Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer a |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. |
|
| November 9, 2023 |
Arcadia Biosciences, Inc. Consolidated Balance Sheets (In thousands, except share data) Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) September 30, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 10,611 $ 20,644 Short-term investments 5,089 — Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 and $3 as of September 30, 2023 and December 31, 2022, respectiv |
|
| August 10, 2023 |
Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Second-Quarter and First-Half 2023 Financial Results and Business Highlights • GoodWheatTMexpands into breakfast category with the launch of better-for-you pancake and waffle mixes • Exiting Body Care to reduce OpEx, focus on Food & Beverage • Exploring strategic opportunities to drive shareholder value DAVIS, Calif. (August 10, 2023) – Arcadia Bio |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. |
|
| August 10, 2023 |
Arcadia Biosciences, Inc. Consolidated Balance Sheets (In thousands, except share data) Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) June 30, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 13,484 $ 20,644 Short-term investments 5,023 — Accounts receivable and other receivables, net of allowance for doubtful accounts of $1 and $3 as of June 30, 2023 and December 31, 2022, respectively 630 1, |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 20, 2023 |
Arcadia Biosciences (RKDA) Announces Strategic Review – Company will explore a range of potential strategies to drive shareholder value – DAVIS, Calif. |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 06, 2023 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 25, 2023 |
Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 ARCADIA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 81-0571538 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 5950 Sherry Lane, Suite 215 Da |
|
| May 25, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Arcadia Biosciences, Inc. |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. |
|
| May 11, 2023 |
Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except share data and per share data) Three Months Ended March 31, 2023 2022 Revenues: Product $ 1,509 $ 3,170 Royalty — 50 Total revenues 1,509 3,220 Operating expenses (income): Cost of revenues 825 3,458 Research and development 359 395 Change in fair value of contingen |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 11, 2023 |
Exhibit 99.1 Arcadia Biosciences (RKDA) Announces First Quarter 2023 Financial Results from Operations and Business Highlights – Significant improvement in gross profit dollars compared to last year – – GoodWheatTM pasta named “Best New Product” by Retail Dietitians Business Alliance – DAVIS, Calif. (May 11, 2023) – Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| April 18, 2023 |
ARCADIA BIOSCIENCES, INC. 2,032,319 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-271082 Prospectus ARCADIA BIOSCIENCES, INC. 2,032,319 Shares of Common Stock This prospectus covers the sale or other disposition from time to time of up to 2,032,319 shares of our common stock, $0.001 par value per share, by the selling stockholders identified in this prospectus, including their transferees, pledgees, donees or succe |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission F |
|
| April 13, 2023 |
Arcadia Biosciences, Inc. 5950 Sherry Lane, Suite 215 Dallas, TX 75225 April 13, 2023 Arcadia Biosciences, Inc. 5950 Sherry Lane, Suite 215 Dallas, TX 75225 April 13, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Conlon Danberg Re: Arcadia Biosciences, Inc. Registration Statement on Form S-3 (No. 333-271082) Request for Acceleration Dear Mr. Danber |
|
| April 3, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Arcadia Biosciences, Inc. |
|
| April 3, 2023 |
As filed with the Securities and Exchange Commission on April 3, 2023. As filed with the Securities and Exchange Commission on April 3, 2023. Registration File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARCADIA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 81-0571538 (State or other jurisdiction of incorporation or organization) ( |
|
| April 3, 2023 |
Securities and Exchange Commission April 3, 2023 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attn: Filing Desk Re: Arcadia Biosciences, Inc. |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-373 |
|
| March 30, 2023 |
Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2022 Financial Results and Business Highlights - Total revenues increased 47% compared to prior year - - Total operating expenses declined 32% year-over-year - - GoodWheatTM pasta in over 1200 stores within 7 months of launch - DAVIS, Calif. (March 30, 2023) – Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and ma |
|
| March 30, 2023 |
EXHIBIT 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of registered securities of Arcadia Biosciences, Inc. (“Arcadia,” “we,” “us,” “our”) is based upon our certificate of incorporation, as amended (“Certificate of Incorporation”) and bylaws, as amended (“Bylaws”) and does not purport to be complete |
|
| March 30, 2023 |
Arcadia Biosciences, Inc. Consolidated Balance Sheets (In thousands, except share data) Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) As of December 31, 2022 2021 Assets Current assets: Cash and cash equivalents $ 20,644 $ 28,685 Accounts receivable and other receivables, net of allowance for doubtful accounts of $3 and $76 as of December 31, 2022 and 2021, respectively 1,287 1,370 Inventories, net — current 2,571 4,4 |
|
| March 3, 2023 |
ARCADIA BIOSCIENCES, INC. 25,981 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-239641 PROSPECTUS SUPPLEMENT (To Prospectus dated September 3, 2020) ARCADIA BIOSCIENCES, INC. 25,981 Shares of Common Stock This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated September 3, 2020 (the “Original Prospectus”), relating to the resale by a selling stockholder named therein |
|
| March 3, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 3, 2023 |
Form of Series A Preferred Investment Option. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 3, 2023 |
ARCADIA BIOSCIENCES, INC. 23,493 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-252659 PROSPECTUS SUPPLEMENT (To Prospectus dated February 11, 2021) ARCADIA BIOSCIENCES, INC. 23,493 Shares of Common Stock This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated February 11, 2021 (the “Original Prospectus”), relating to the resale by a selling stockholder named therein |
|
| March 3, 2023 |
Form of Series B Preferred Investment Option. EX-4 4 rkda-ex43.htm EX-4.3 Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURS |
|
| March 3, 2023 |
Form of Placement Agent Preferred Investment Option. Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 3, 2023 |
Form of Investment Option Amendment, dated as of March 2, 2023. Exhibit 10.3 March 2, 2023 Holder of Preferred Investment Options to Purchase Common Stock Re: Amendment to Existing Preferred Investment Options Dear Holder: Reference is hereby made to the private placement on or about the date hereof (the “Offering”) by Arcadia Biosciences, Inc. (the “Company”) of shares of common stock, par value $0.001 per share (“Common Stock”), and/or other securities of th |
|
| March 3, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 2, 2023, between Arcadia Biosciences, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purcha |
|
| March 3, 2023 |
ARCADIA BIOSCIENCES, INC. 119,313 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267637 PROSPECTUS SUPPLEMENT (To Prospectus dated October 5, 2022) ARCADIA BIOSCIENCES, INC. 119,313 Shares of Common Stock This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated February 8, 2022 (the “Original Prospectus”), relating to the resale by a selling stockholder named therein of |
|
| March 3, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 2, 2023 between Arcadia Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 02, 2023 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 3, 2023 |
ARCADIA BIOSCIENCES, INC. 9,892 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-235446 PROSPECTUS SUPPLEMENT (To Prospectus dated December 20, 2020) ARCADIA BIOSCIENCES, INC. 9,892 Shares of Common Stock This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated December 20, 2020 (the “Original Prospectus”), relating to the resale by a selling stockholder named therein o |
|
| March 3, 2023 |
ARCADIA BIOSCIENCES, INC. 16,367 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262407 PROSPECTUS SUPPLEMENT (To Prospectus dated February 8, 2022) ARCADIA BIOSCIENCES, INC. 16,367 Shares of Common Stock This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated February 8, 2022 (the “Original Prospectus”), relating to the resale by a selling stockholder named therein of |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 28, 2023 |
Amendment to the Amended and Restated Certificate of Incorporation of Registrant. EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARCADIA BIOSCIENCES, INC. Arcadia Biosciences, Inc., a corporation organized under and existing under the laws of the State of Delaware (the “Corporation”), certifies that: FIRST: The name of the Corporation is Arcadia Biosciences, Inc. SECOND: The Board of Directors of the Corporation, acting in accor |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2023 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 14, 2023 |
RKDA / Arcadia Biosciences Inc / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-rkda123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Arcadia Biosciences, Inc. (Name of Issuer) Common (Title of Class of Securities) 039014204 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 20, 2023 |
RKDA / Arcadia Biosciences Inc / Moral Compass Corp - SC 13D/A Activist Investment SC 13D/A 1 d419453dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) ARCADIA BIOSCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 039014204 (CUSIP Number) Philip W. Peters Farella Braun + Martel LLP Russ Building 235 Montgomery Street San Francisco, Californi |
|
| January 6, 2023 |
DEF 14A 1 rkda-def14areversestock.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 03, 2023 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Inc |
|
| January 5, 2023 |
Employment Letter and Severance and Change in Control Agreement for Thomas J. Schaefer. EX-10.1 2 rkda-ex101.htm EX-10.1 Exhibit 10.1 January 3, 2023 Thomas Schaefer [Address] Dear Thomas: This letter sets forth the terms of your employment as Chief Financial Officer of Arcadia Biosciences, Inc. (the “Company”), as of January 3, 2023 (the “Effective Date”). The terms set forth below shall be effective as of the Effective Date. Reporting and Base Salary. You will report to the Preside |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 07, 2022 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 8, 2022 |
Certificate of Designation of Series A Preferred Stock. Exhibit 3.1 ARCADIA BIOSCIENCES, INC. CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Arcadia Biosciences, Inc., a Delaware corporation (the ?Corporation?), that the following resolution was duly adopted by the board of directors of the Corporation (the ?Board of |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Arcadia Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 81-0571538 (I.R.S. employer identification |
|
| December 8, 2022 |
Amendment to the Amended and Restated Bylaws of Registrant. Exhibit 3.2 AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF ARCADIA BIOSCIENCES, INC. Article II of the Amended and Restated Bylaws of Arcadia Biosciences, Inc., a Delaware corporation (as amended, the ?Bylaws?), is hereby amended as follows: Article II, Section 2.5 of the Bylaws, is hereby amended to read in its entirety as follows: ?QUORUM. At any meeting of stockholders, the holders of a one-th |
|
| November 30, 2022 |
Arcadia Biosciences (RKDA) Announces CFO Transition - Pam Haley to be replaced by Thomas J. |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 10, 2022 |
Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Strong Third Quarter 2022 Financial Results and Business Highlights - GoodWheatTM Pasta distribution doubles from Q2 - - Gross margins improve to 28% - - Streamlined operations focus on higher-margin brands - DAVIS, Calif. (November 10, 2022) ? Arcadia Biosciences, Inc.? (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and |
|
| November 10, 2022 |
Arcadia Biosciences, Inc. Consolidated Balance Sheets (In thousands, except share data) Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) 1 September 30, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 22,719 $ 28,685 Accounts receivable and other receivables, net of allowance for doubtful accounts of $13 and $76 as of September 30, 2022 and December 31, 2021, respectively 2,726 1,370 Inventories |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. |
|
| October 7, 2022 |
ARCADIA BIOSCIENCES, INC. Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-267637 Prospectus ARCADIA BIOSCIENCES, INC. 4,958,631 Common Stock Pursuant to this prospectus, the selling stockholders identified herein are offering on a resale basis an aggregate of 4,958,631 shares of our common stock that are issuable upon the exercise of outstanding preferred investment options. These preferred investment optio |
|
| October 4, 2022 |
Arcadia Biosciences, Inc. 202 Cousteau Place, Suite 105 Davis, CA 95618 October 4, 2022 Arcadia Biosciences, Inc. 202 Cousteau Place, Suite 105 Davis, CA 95618 October 4, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Cindy Polynice Re: Arcadia Biosciences, Inc. Registration Statement on Form S-1 (No. 333-267637) Request for Acceleration Dear Ms. Polynice: Pursuant to Rule |
|
| September 27, 2022 |
EX-FILING FEES 6 rkda-exfilingfees225.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Arcadia Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Off |
|
| September 27, 2022 |
As filed with the Securities and Exchange Commission on September 27, 2022. As filed with the Securities and Exchange Commission on September 27, 2022. Registration File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARCADIA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 2870 81-0571538 (State or other jurisdiction of incorporation or organ |
|
| September 27, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 16, 2022 |
Form of Investor Preferred Investment Option. EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 16, 2022 |
Form of Investor Pre-Funded Warrant. EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT arcadia biosciences, inc. Warrant Shares: Issue Date: August 16, 2022 Initial Exercise Date: August 16, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fort |
|
| August 16, 2022 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of August 12, 2022 between Arcadia Biosciences, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditi |
|
| August 16, 2022 |
Exhibit 99.1 Execution Version August 12, 2022 STRICTLY CONFIDENTIAL Arcadia Biosciences, Inc. 202 Cousteau Place, Suite 105 Davis, California 9561 Attn: Stanley E. Jacot, Jr., President and Chief Executive Officer Dear Mr. Jacot: This letter agreement (this ?Agreement?) constitutes the agreement between Arcadia Biosciences, Inc. (the ?Company?) and H.C. Wainwright & Co., LLC (?Wainwright?), that |
|
| August 16, 2022 |
Form of Placement Agent Preferred Investment Option. EXHIBIT 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 16, 2022 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-264425 PROSPECTUS SUPPLEMENT (To Prospectus dated May 12, 2022) ARCADIA BIOSCIENCES, INC. 2,450,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 2,272,506 Shares of Common Stock Up to 2,272,506 Shares of Common Stock underlying the Pre-Funded Warrants We are offering to a single institutional investor 2,450,000 shares of our com |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 11, 2022 |
Arcadia Biosciences, Inc. Consolidated Balance Sheets (In thousands, except share data) Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) June 30, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 21,234 $ 28,685 Accounts receivable, net of allowance for doubtful accounts of $89 and $76 as of June 30, 2022 and December 31, 2021, respectively 3,854 1,370 Inventories, net ? current 3,275 4,433 Assets |
|
| August 11, 2022 |
EX-99.1 2 rkda-ex991.htm EX-99.1 Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Strong Second-Quarter and First-Half 2022 Financial Results and Business Highlights – Revenue increased 175% from Q2 2021 – – GoodWheatTM pasta successfully launched in retail and online – – $2M milestone achievement recognized for HB4® soybean approval in China – DAVIS, Calif. (August 11, 2022) – Arcadia Bioscience |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. |
|
| June 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2022 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 31, 2022 |
Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 ARCADIA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 81-0571538 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 202 Cousteau Place, Suite 105 |
|
| May 31, 2022 |
EX-FILING FEES 4 rkda-exfilingfees23.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Arcadia Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate |
|
| May 12, 2022 |
Arcadia Biosciences, Inc. Consolidated Balance Sheets (In thousands, except share data) EX-99.2 3 rkda-ex992.htm EX-99.2 Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) March 31, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 24,551 $ 28,685 Accounts receivable, net of allowance for doubtful accounts of $54 and $76 as of March 31, 2022 and December 31, 2021, respectively 2,768 1,370 Inventorie |
|
| May 12, 2022 |
Employment Letter for Stanley E. Jacot Jr., Chief Executive Officer Exhibit 10.1 January 31, 2022 Stan Jacot [***Address Redacted***] Dear Stan: On behalf of Arcadia Biosciences, Inc., henceforth the ?Company,? it is my pleasure to offer you the position of Chief Executive Officer. This letter constitutes the entire agreement relating to the terms of your employment, except for the Confidentiality and Invention Assignment Agreement between you and the Company (whi |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 12, 2022 |
Exhibit 99.1 Arcadia Biosciences (RKDA) Announces First Quarter 2022 Financial Results ? Sales increased 48% from Q4 2021 ? ? First retail orders of Good WheatTM pasta shipped ? - HB4? soybeans approved in China, $2M milestone anticipated - DAVIS, Calif. (May 12, 2022) ? Arcadia Biosciences, Inc.? (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, toda |
|
| May 10, 2022 |
Arcadia Biosciences, Inc. 202 Cousteau Place, Suite 105 Davis, CA 95618 May 10, 2022 Arcadia Biosciences, Inc. 202 Cousteau Place, Suite 105 Davis, CA 95618 May 10, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Celeste Murphy Re: Arcadia Biosciences, Inc. Registration Statement on Form S-3 (No. 333-264425) Request for Acceleration Dear Celeste Murphy: Pursuant to Rule 4 |
|
| April 21, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Arcadia Biosciences, Inc. |
|
| April 21, 2022 |
As filed with the Securities and Exchange Commission on April 21, 2022 As filed with the Securities and Exchange Commission on April 21, 2022 Registration No. |
|
| April 19, 2022 |
Definitive Proxy Statement on Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| April 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-373 |
|
| March 31, 2022 |
Severance and Change In Control Agreement for Chris Cuvelier. Exhibit 10.27 SEVERANCE AND CHANGE IN CONTROL AGREEMENT This Severance and Change in Control Agreement (the ?Agreement?) is made and entered into by and between Chris Cuvelier (?Executive?) and Arcadia Biosciences, Inc. (the ?Company?), effective as of July 20, 2021 (the ?Effective Date?). RECITALS 1. The Compensation Committee of the Board of Directors of the Company (the ?Committee?) recognizes |
|
| March 30, 2022 |
Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2021 Financial Results and Business Highlights ? Strong balance sheet entering 2022 ? ? Expanded consumer product offerings in on-trend categories ? ? Experienced CPG talent added throughout organization ? DAVIS, Calif. (March 30, 2022) ? Arcadia Biosciences, Inc.? (Nasdaq: RKDA), a producer and marketer of innovative, |
|
| March 30, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 30, 2022 |
Arcadia Biosciences, Inc. Consolidated Balance Sheets (In thousands, except share data) Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) As of December 31, 2021 2020 Assets Current assets: Cash and cash equivalents $ 28,685 $ 14,042 Short-term investments ? 11,625 Accounts receivable, net of allowance for doubtful accounts of $76 and $0 as of December 31, 2021 and 2020, respectively 1,370 1,406 Inventories, net ? current |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Arcadia Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 039014204 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 11, 2022 |
ARCADIA BIOSCIENCES, INC. Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-262407 Prospectus ARCADIA BIOSCIENCES, INC. 2,749,591 Common Stock Pursuant to this prospectus, the selling stockholders identified herein are offering on a resale basis an aggregate of 2,749,591 shares of our common stock that are issuable upon the exercise of outstanding warrants to purchase our common stock. These warrants were iss |
|
| February 7, 2022 |
EX-99.1 4 rkda-ex991.htm EX-99.1 Exhibit 99.1 Arcadia Biosciences (RKDA) Names Stan Jacot as CEO Transformational change leader and CPG veteran brings 30 years of experience building high-functioning teams, driving organizational growth DAVIS, Calif. (February 2, 2022) – Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, has |
|
| February 7, 2022 |
Severance and Change in Control Agreement for Stanley E. Jacot, Jr. Exhibit 10.1 SEVERANCE AND CHANGE IN CONTROL AGREEMENT This Severance and Change in Control Agreement (the ?Agreement?) is made and entered into by and between Stan Jacot (?Executive?) and Arcadia Biosciences, Inc. (the ?Company?), effective as of the latest date set forth by the signatures of the parties hereto below (the ?Effective Date?). RECITALS 1. The Compensation Committee of the Board of D |
|
| February 7, 2022 |
Inducement Option Grant for Stanley E. Jacot, Jr. Exhibit 10.2 ARCADIA BIOSCIENCES, INC. INDUCEMENT STOCK OPTION AWARD AGREEMENT NOTICE OF INDUCEMENT STOCK OPTION GRANT Participant?s Name and Address: Stanley E. Jacot, Jr. 3940 Stanford Avenue Dallas, TX 75225 You (?Participant?) have been granted a U.S. Nonstatutory Stock Option (the ?Option?) to purchase shares of Common Stock of Arcadia Biosciences, Inc. (the ?Company?), outside of the Arcadia |
|
| February 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 02, 2022 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 4, 2022 |
RKDA / Arcadia Biosciences Inc / Hudson Bay Capital Management LP - RKDA 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Arcadia Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 039014204 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 3, 2022 |
Arcadia Biosciences, Inc. 202 Cousteau Place, Suite 105 Davis, CA 95618 February 3, 2022 Arcadia Biosciences, Inc. 202 Cousteau Place, Suite 105 Davis, CA 95618 February 3, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Arcadia Biosciences, Inc. Registration Statement on Form S-1 (No. 333-262407) Request for Acceleration Dear Mr. Buchmiller: Pursuant to Ru |
|
| January 28, 2022 |
List of subsidiaries of the Registrant. EX-21.1 3 rkda-ex211170.htm EX-21.1 EXHIBIT 21.1 SUBSIDIARIES OF ARCADIA BIOSCIENCES, INC. Name State/Jurisdiction of Formation Arcadia Wellness, LLC Delaware |
|
| January 28, 2022 |
As filed with the Securities and Exchange Commission on January 28, 2022. As filed with the Securities and Exchange Commission on January 28, 2022. Registration File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARCADIA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 2870 81-0571538 (State or other jurisdiction of incorporation or organiz |
|
| December 20, 2021 |
Separation and Release Agreement Exhibit 10.1 SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement ("Agreement") is entered into by and between MATTHEW PLAVAN (?Plavan? or ?Employee?) on the one hand and ARCADIA BIOSCIENCES, INC., a Delaware corporation (?Arcadia? or ?Company?) on the other hand. The parties may hereinafter be referred to individually as a "Party" or collectively as the "Parties." BACKGROUND A. |
|
| December 20, 2021 |
Arcadia Biosciences (RKDA) Appoints Kevin Comcowich to Interim CEO Arcadia Biosciences (RKDA) Appoints Kevin Comcowich to Interim CEO DAVIS, Calif. (December 20, 2021) ? Arcadia Biosciences, Inc.? (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has appointed Kevin Comcowich, current Chairman of the Arcadia Board of Directors, as interim chief executive officer, effective January 1, 2022, as the board o |
|
| December 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. |
|
| November 15, 2021 |
Severance and Change In Control Agreement for Laura Pitlik. Exhibit 10.2 SEVERANCE AND CHANGE IN CONTROL AGREEMENT This Severance and Change in Control Agreement (the ?Agreement?) is made and entered into by and between Laura Pitlik (?Executive?) and Arcadia Biosciences, Inc. (the ?Company?), effective as of July 12, 2021 (the ?Effective Date?). RECITALS 1. The Compensation Committee of the Board of Directors of the Company (the ?Committee?) recognizes tha |
|
| November 15, 2021 |
Employment letter for Laura Pitlik, Chief Marketing Officer. Exhibit 10.1 June 24, 2021 Laura Pitlik Dear Laura: This letter sets forth the terms of your employment as Chief Marketing Officer of Arcadia Biosciences, Inc. (the ?Company?), which will commence on July 12, 2021 (the ?Effective Date?). The terms set forth below shall be effective as of the Effective Date. Reporting and Base Salary. You will report to the President and Chief Executive Officer, Ma |
|
| November 15, 2021 |
Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Strong Third-Quarter Financial Results and Business Highlights Revenues for quarter up six-fold, year-to-date up four-fold DAVIS, Calif. (November 15, 2021) ? Arcadia Biosciences, Inc.? (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the third qua |
|
| October 12, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 30, 2021 (Date of earliest event reported) Arcadia Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorp |
|
| September 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 03, 2021 Arcadia Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 7, 2021 |
Exhibit 99.1 Arcadia Biosciences Announces Leadership Transition - Company seeks new CEO as it further expands into consumer packaged goods; Matt Plavan to step down when successor is named - DAVIS, Calif., September 7, 2021 - Arcadia Biosciences, Inc.? (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced that it has launched a national search |
|
| September 7, 2021 |
Exhibit 10.1 TRANSITION AGREEMENT This Transition Agreement (?Agreement?) is entered into by and between Arcadia Biosciences, Inc., a Delaware corporation (?Company?) and Matthew Plavan (?Executive?), effective as of September 3, 2021 (?Effective Date?). The parties agree as follows: 1. Background and Purpose. 1.1 Employment. Executive currently is employed as the Chief Executive Officer of the Co |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. |
|
| August 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 16, 2021 (Date of earliest event reported) Arcadia Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 16, 2021 |
Employment letter for Chris Cuvelier, Chief Growth Officer. EX-10.1 2 rkda-ex101148.htm EX-10.1 Exhibit 10.1 May 17, 2021 Chris Cuvelier Dear Chris: This letter sets forth the terms of your employment as Chief Growth Officer of Arcadia Biosciences, Inc. (the “Company”), which will commence on May 17, 2021 (the “Effective Date”). The terms set forth below shall be effective as of the Effective Date. Reporting and Base Salary. You will report to the Presiden |
|
| August 16, 2021 |
EX-99.1 2 rkda-ex9916.htm EX-99.1 Exhibit 99.1 Arcadia Biosciences Announces Strong Second-Quarter and First-Half 2021 Financial Results and Business Highlights Revenues for quarter up five-fold, year-to-date up four-fold DAVIS, Calif. (August 16, 2021) – Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its f |
|
| August 2, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 17, 2021 (Date of earliest event reported) Arcadia Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorpo |
|
| August 2, 2021 |
Exhibit 99.3 COCONUT WATER LINE OF LIVE ZOLA, LLC AUDITED FINANCIAL STATEMENTS DECEMBER 31, 2020 COCONUT WATER LINE OF LIVE ZOLA, LLC AUDITED FINANCIAL STATEMENTS DECEMBER 31, 2020 CONTENTS Independent Auditors? Report 1 Financial Statements: Balance Sheet 2 Statements of Operations and Parent Equity 3 Statement of Cash Flows 4 Notes to Financial Statements 5-9 Independent Auditor's Report To the |
|
| August 2, 2021 |
Rever holdings, LLC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET Exhibit 99.2 REVER HOLDINGS, LLC Condensed Consolidated Financial Statements As Of March 31, 2021 And For The Three Months Ended March 31, 2021 rever holdings, LLC INDEX TO condensed CONSOLIDATED FINANCIAL STATEMENTS Page CONDENSED CONSOLIDATED FINANCIAL STATEMENTS: Unaudited Condensed Consolidated Balance Sheet 3 Unaudited Condensed Consolidated Statement of Operations 4 Unaudited Condensed Conso |
|
| August 2, 2021 |
EX-99.4 7 rkda-ex99492.htm EX-99.4 Exhibit 99.4 COCONUT WATER LINE OF LIVE ZOLA, LLC UNAUDITED FINANCIAL STATEMENTS MARCH 31, 2021 COCONUT WATER LINE OF LIVE ZOLA, LLC UNAUDITED FINANCIAL STATEMENTS MARCH 31, 2021 CONTENTS Unaudited Financial Statements: Balance Sheet 2 Statements of Operations & Parent Equity 3 Statement of Cash Flows 4 Notes to Financial Statements 5-9 COCONUT WATER LINE OF LIVE |
|
| August 2, 2021 |
Exhibit 99.5 Arcadia Biosciences, Inc. and EKO Holdings, LLC, Lief Holdings, LLC and Live Zola, LLC Unaudited Pro Forma Condensed Consolidated Combined Financial Statements The following unaudited pro forma condensed consolidated combined balance sheet as of March 31, 2021 and the unaudited pro forma condensed consolidated combined statements of operations for the year ended December 31, 2020 and |
|
| August 2, 2021 |
EXhibit 99.1 REVER HOLDINGS, LLC. Consolidated Financial Statements For The Year Ended And As Of December 31, 2020 rever holdings, LLC. INDEX TO cONSOLIDATED FINANCIAL STATEMENTS Page INDEPENDENT AUDITOR'S REPORT 3 CONSOLIDATED FINANCIAL STATEMENTS: Consolidated Balance Sheet 4 Consolidated Statement of Operations 5 Consolidated Statement of Changes in Member's Deficit 6 Consolidated Statement of |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 12, 2021 (Date of earliest event reported) Arcadia Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 6, 2021 |
Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2021 Arcadia Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 2, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2021 Arcadia Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Suppl |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 Arcadia Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Suppl |
|
| May 28, 2021 |
Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 ARCADIA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 81-0571538 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 202 Cousteau Place, Suite 105 |
|
| May 28, 2021 |
2021 Form of Inducement Option Grant EXHIBIT 10.3 ARCADIA BIOSCIENCES, INC. INDUCEMENT STOCK OPTION AWARD AGREEMENT NOTICE OF INDUCEMENT STOCK OPTION GRANT Participant?s Name and Address: You (?Participant?) have been granted a U.S. Nonstatutory Stock Option (the ?Option?) to purchase shares of Common Stock of Arcadia Biosciences, Inc. (the ?Company?), outside of the Arcadia Biosciences, Inc. 2015 Omnibus Equity Incentive Plan, as am |
|
| May 21, 2021 |
EXHIBIT 10.1 CERTAIN SCHEDULES AND EXHIBITS TO THIS DOCUMENT HAVE BEEN OMITTED BECAUSE THEY CONTAIN CONFIDENTIAL AND/OR NON-MATERIAL INFORMATION AND WOULD LIKELY CAUSE COMPETITIVE HARM TO ARCADIA BIOSCIENCES, INC. IF PUBLICLY DISCLOSED. THE EXHIITS AND SCHEDULES, AND THE SUBJECT MATTER THEREOF, ARE DESCRIBED IN THIS DOCUMENT. Asset Purchase Agreement by and among ARCADIA BIOSCIENCES, INC. a Delawa |
|
| May 21, 2021 |
Inducement Option Grant for Chris Cuvelier. EXHIBIT 10.2 ARCADIA BIOSCIENCES, INC. INDUCEMENT STOCK OPTION AWARD AGREEMENT NOTICE OF INDUCEMENT STOCK OPTION GRANT Participant?s Name and Address: Chris Cuvelier [***Address Redacted***] You (?Participant?) have been granted a U.S. Nonstatutory Stock Option (the ?Option?) to purchase shares of Common Stock of Arcadia Biosciences, Inc. (the ?Company?), outside of the Arcadia Biosciences, Inc. 2 |
|
| May 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 17, 2021 (Date of earliest event reported) Arcadia Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 17, 2021 |
Arcadia Biosciences (RKDA) Announces First-Quarter 2021 Financial Results and Business Highlights Exhibit 99.1 Arcadia Biosciences (RKDA) Announces First-Quarter 2021 Financial Results and Business Highlights - Revenues up for the quarter over 160%, liquidity strengthened - - Acquires Lief assets, a premium portfolio of CBD and wellness brands, bringing immediate top-line revenue, manufacturing capabilities, retail network and proven leadership in consumer goods industry - - Acquires European |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. |
|
| May 17, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 17, 2021 (Date of earliest event reported) Arcadia Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-373 |
|
| March 30, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 30, 2021 (Date of earliest event reported) Arcadia Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 30, 2021 |
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2020 Financial Results and Business Highlights – Record revenues, up six-fold over prior year – – Strong balance sheet entering 2021 – – Expanded product offerings – DAVIS, Calif. |
|
| February 24, 2021 |
Exhibit 99.1 Arcadia Biosciences Welcomes Debbie Carosella to Board Of Directors - Prominent leader in consumer food industry will help guide commercialization strategy for innovative health and nutrition ingredients - DAVIS, Calif. (February 24, 2021) – Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food |
|
| February 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2021 Arcadia Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 12, 2021 |
ARCADIA BIOSCIENCES, INC. Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-252659 Prospectus ARCADIA BIOSCIENCES, INC. 12,209,015 Common Stock This prospectus covers the sale or other disposition from time to time of up to 12,209,015 shares of our common stock, $0.001 par value per share, by the selling stockholders identified in this prospectus, including their transferees, pledgees, donees or successors. T |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Arcadia Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 039014204 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 9, 2021 |
Arcadia Biosciences, Inc. 202 Cousteau Place, Suite 105 Davis, CA 95618 February 9, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention:Jordan Metoyer Re: Arcadia Biosciences, Inc. Registration Statement on Form S-3 (No. 333-252659) Request for Acceleration Dear Jordan Metoyer: Pursuant to Rule 461 promulgated under |
|
| February 2, 2021 |
As filed with the Securities and Exchange Commission on February 2, 2021. Registration File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARCADIA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 81-0571538 (State or other jurisdiction of incorporation or organization |
|
| January 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2021 Arcadia Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37383 81-0571538 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 29, 2021 |
EX-10.2 5 rkda-ex10212.htm EX-10.2 EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 25, 2021, between Arcadia Biosciences, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is |
|
| January 29, 2021 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 25, 2021 between Arcadia Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| January 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Arcadia Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 039014204 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
